Amikacin Sulfate and Jivi Intravenous

• Generic Name: amikacin
• Dosage Forms: n.a.
• Other Brand Names: Amikin, Amikin Pediatric

Treatment of serious bone and joint infections caused by susceptible gram-negative bacteria.

Treatment of serious intra-abdominal infections (including peritonitis) caused by susceptible gram-negative bacteria. Used as an adjunct to other appropriate anti-infectives (e.g., clindamycin, metronidazole, piperacillin and tazobactam, ampicillin and sulbactam).

Treatment of meningitis caused by susceptible gram-negative bacteria.

Aminoglycosides should not be used alone for treatment of meningitis; usually used as an adjunct to other anti-infectives in initial treatment.

Used in conjunction with ampicillin for initial empiric treatment of neonatal S. agalactiae meningitis or for Listeria monocytogenes meningitis in children. Used in conjunction with a third-generation cephalosporin for neonatal gram-negative bacterial meningitis, including infections caused by E. coli. Has been used concomitantly with imipenem in adults for treatment of meningitis caused by E. coli, concomitantly with meropenem for treatment of meningitis caused by Pseudomonas, or concomitantly with imipenem or colistin (commercially available as colistimethate sodium) for treatment of meningitis caused by Acinetobacter.

Treatment of serious respiratory tract infections caused by susceptible gram-negative bacteria.

Used as an adjunct to an appropriate β-lactam (e.g., ceftriaxone, cefotaxime, cefepime, piperacillin and tazobactam, ticarcillin and clavulanate) or carbapenem (e.g., imipenem, meropenem) for empiric treatment of nosocomial pneumonia.

Treatment of septicemia caused by susceptible gram-negative bacteria.

Used as an adjunct to an appropriate β-lactam (e.g., ceftriaxone, cefotaxime, cefepime, piperacillin and tazobactam, ticarcillin and clavulanate) or carbapenem (e.g., imipenem, meropenem) for empiric treatment of life-threatening septicemia.

Treatment of serious skin and skin structure infections caused by susceptible gram-negative bacteria.

Treatment of serious complicated and recurrent UTIs caused by susceptible gram-negative bacteria, including Enterobacteriaceae or Pseudomonas aeruginosa. Used as an adjunct to other appropriate anti-infectives.

Not indicated for uncomplicated UTIs unless causative organism is resistant to other less-toxic alternatives.

Second-line agent for use in multiple-drug regimens for treatment of active tuberculosis in patients with relapse, treatment failure, or Mycobacterium tuberculosis resistant to isoniazid and/or rifampin or when first-line drugs cannot be tolerated.

Alternative for use in multiple-drug regimens for treatment of M. avium complex (MAC) infections.

Treatment of nonpulmonary infections caused by M. abscessus, M. chelonae, or M. fortuitum.

Treatment of infections caused by Nocardia.

Sulfonamides (usually co-trimoxazole) are treatment of choice for most Nocardia infections; concomitant use of amikacin, imipenem, and/or ceftriaxone recommended for initial treatment of severe or disseminated infections. When sulfonamides cannot be used, regimens containing amikacin, a carbapenem (imipenem or meropenem), a third-generation cephalosporin (ceftriaxone), a tetracycline (doxycycline, minocycline), fixed combination of amoxicillin and clavulanate, clarithromycin, cycloserine, or linezolid are recommended.

Treatment of infections caused by Rhodococcus equi.

Empiric anti-infective therapy of presumed bacterial infections in febrile neutropenic patients. Used in conjunction with an appropriate antipseudomonal cephalosporin (e.g., ceftazidime, ceftriaxone, cefepime), extended-spectrum penicillin (e.g., piperacillin and tazobactam, ticarcillin and clavulanate), or carbapenem (e.g., imipenem, meropenem).

Consult published protocols for the treatment of infections in febrile neutropenic patients for specific recommendations regarding selection of the initial empiric regimen, when to change the initial regimen, possible subsequent regimens, and duration of therapy in these patients. Consultation with an infectious disease expert knowledgeable about infections in immunocompromised patients also is advised.

• Generic Name: antihemophilic factor
• Dosage Forms: n.a.
• Other Brand Names: Jivi, Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil-M, Koate-DVI, Monoclate-P, Obizur

Antihemophilic factor (recombinant) pegylated-aucl injection is used to treat and control bleeding in patients with hemophilia A (congenital Factor VIII deficiency) who have been treated before. It is also used to reduce the number of bleeding episodes in patients when used regularly. Antihemophilic factor (recombinant) pegylated-aucl injection is also used to prevent bleeding during a surgical procedure.

This medicine is available only with your doctor's prescription.